Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly low-dose emicizumab prophylaxis without loading doses in haemophilia A
TCTR20250720003Phase 3Not yet recruiting
- Sponsor
- N/A
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by N/A. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on TCTR20250720003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250720003.